No Data
No Data
No Data
No Data
No Data
Express News | Lineage Cell Therapeutics Inc May Offer And Sell Common Shares Of Up To $40M From Time To Time Through Or To B. Riley
Moomoo 24/7Mar 22 16:36 ET
Optimistic Buy Rating for Lineage Cell Therapeutics Ahead of OpRegen Study Data Release
TipRanksMar 19 01:46 ET
15 Best Anti-Aging Foods for Youthful Skin
Yahoo FinanceMar 18 10:31 ET
Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium
Business WireMar 18 08:00 ET
RG6501 (OpRegen) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
Business WireMar 13 08:00 ET
RG6501 (OpRegen) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that preclinical results as part of a
BusinesswireMar 11 08:00 ET
No Data
No Data
Kevin Lehmann : 930am bullish rise friday
Kevin Lehmann : slow pullback till 1130am